Novartis Battles Image Problem In Japan As Data Manipulation Questions Remain
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharmaceuticals Head David Epstein visited Tokyo to announce salary cuts to the company’s top Japan staff and to introduce a new Japan chairman after acknowledging undisclosed conflict of interest in recalled Diovan studies. But the company is still dogged by its involvement in data manipulation and improper advertising after interim results from a MHLW investigation.
You may also be interested in...
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.